目的 系统评价连花清瘟治疗新型冠状病毒肺炎（coronavirus disease，COVID-19）的疗效情况，为COVID-19临床治疗提供依据。方法 计算机检索中国知网、万方、维普、CBM、PubMed及Cochrane Library等数据库，检索时间截至2020年5月27日。采用Cochrane协作网偏倚风险工具对纳入研究进行风险评估及质量评价，Stata 15软件进行Meta分析，Begg’s检验分析发表偏倚。结果 最终纳入7项临床疗效研究，包括665例COVID-19患者。Meta分析结果显示，与西医单独治疗相比，连花清瘟联合西医治疗可明显改善COVID-19患者的主要临床症状有效率[RR=1.24，95% CI（1.12，1.38），P<0.05]，CT好转情况[RR=1.14，95% CI （1.02，1.28），P<0.05]及降低临床转重型比例[RR=0.48，95% CI（0.31，0.72），P<0.05]；此外，连花清瘟联合治疗可有效缩短COVID-19患者的发热持续时间[SMD=-0.87，95% CI（-1.22，-0.52），P<0.05]、临床症状消失时间[SMD=-1.19，95% CI（-1.56，-0.82），P<0.05]及住院时间[SMD=-0.61，95% CI（-0.91，-0.30），P<0.05]。结论 连花清瘟作为辅助治疗可有效改善COVID-19患者的临床症状及CT好转情况。

Objective To systematically evaluate the efficacy of Lianhua Qingwen (LQC) on COVID-19, and provide evidence for the formulation and optimization of clinical therapy on COVID-19. Methods Six databases (PubMed, Cochrane Library, Wanfang, Weipu, CBM and CNKI) were searched up to May 27, 2020. The Cochrane collaborative bias risk tool was used for risk evaluation and quality assessment; Meta-analysis was carried out by Stata 15 software. Begg’s test was used for publication bias. Results Seven clinical trials were included with 665 COVID-19 patients. Compared with Western medicine alone, integrated Lianhua Qingwen significantly improved the effective rate of clinical symptoms [RR=1.24, 95% CI (1.12, 1.38), P<0.05] of COVID-19, increased CT improvement [RR=1.14, 95% CI (1.02, 1.28), P<0.05] and reduced the proportion of progressing into sever clinical level [RR=0.48, 95% CI (0.31, 0.72), P<0.05]; In addition, integrated Lianhua Qingwen could effectively shorten the duration of fever [SMD=-0.87, 95% CI (-1.22,-0.52), P<0.05], time of clinical symptoms disappearance [SMD=-1.19, 95% CI (-1.56, -0.82), P<0.05] and hospital stay [SMD=-0.61, 95% CI (-0.91, -0.30), P<0.05]. Conclusion Lianhua Qingwen could be used as adaptive and complementary medicine to improve clinical symptoms and CT for COVID-19.

R28

国家自然科学基金资助项目（81960614）